STYLAGE® XL BI-FLEX® with Lidocaine

STYLAGE® XL BI-FLEX® with Lidocaine — Injectable HA Dermal Filler for Deep Volumisation, Severe Volume Loss & Structural Facial Contouring

Product Specifications

• Drug Class: Injectable hyaluronic acid dermal filler (cross-linked, deep plane, highest concentration in the STYLAGE® range, with mannitol and lidocaine)
• Active Ingredients: Hyaluronic acid (cross-linked) 26mg/g; Mannitol 9mg/g; Lidocaine 3mg/g
• Manufacturer: Laboratories VIVACY
• Brand: STYLAGE®
• Country of Origin: France
• Strength: 26mg/g HA; 9mg/g Mannitol; 3mg/g Lidocaine
• Dosage Form: Injectable gel — 2 × 1mL prefilled syringes (BI-FLEX® syringe system) + 2 × 23G 1¼” needles + 2 × 27G ½” needles
• FDA Status: Not currently approved by the US FDA
• Regulatory Status: CE-marked (EU); current as of 2026

Mechanism of Action & Why Delivery Choices Matter

At 26mg/g, STYLAGE® XL BI-FLEX® with Lidocaine features the highest HA concentration in the STYLAGE® line. When placed into the deep subcutaneous or supraperiosteal plane, the cross-linked HA integrates into surrounding tissue, binding water to deliver sustained, high-volume structural support.

The clinical performance of this deep-plane formulation relies on three core pillars:

• IPN-Like Technology™ (Dual-Network Architecture): Two interlocked HA polymer chains are embedded within a single gel matrix. This produces superior cohesivity, elasticity, and resistance to mechanical deformation compared to conventional single-network fillers—essential for maintaining contour in high-movement zones like the cheeks and jawline.
• Antioxidant Stabilization (9mg/g Mannitol): Acts as a powerful free radical scavenger that inhibits oxidative degradation immediately after injection. By neutralizing trauma-induced free radicals, mannitol shields the heavy HA matrix, supporting an extended clinical longevity of 12 to 18 months.
• Targeted Pain Management (3mg/g Lidocaine): Deep structural injections generate significantly more discomfort than shallow corrections. As an amide-type local anesthetic, the co-formulated lidocaine blocks voltage-gated sodium channels to interrupt pain signals instantly, eliminating the need for separate anesthetic steps and maximizing patient tolerability.

The Deep-Depth Needle Logic

The dual-needle configuration supplied in each box is directly tailored to manage the extrusion physics and viscosity demands of a heavy 26mg/g gel:

• 23G 1¼” Needles: Engineered to overcome resistance during deep bolus placement on the periosteum or to establish smooth entry points for cannula delivery.
• 27G ½” Needles: High-caliber, ultra-thin-walled needles optimized for finer, more controlled subcutaneous delivery where precision micro-contouring is the priority.

Clinical Reversibility

Despite its high concentration and dense dual-network interlocking architecture, the STYLAGE® XL matrix remains fully and rapidly reversible via standard hyaluronidase injection.

About STYLAGE® XL BI-FLEX® with Lidocaine — The Rebrand & Its Place in the STYLAGE® Line

Previously marketed as STYLAGE® XL with the Bi-SOFT® syringe, the BI-FLEX® rebrand reflects improvements in syringe ergonomics, injection precision, and safety — not a change to the active formulation. Practitioners reordering should use the teal-and-white packaging as their procurement identifier. When buying online, confirming the current BI-FLEX® presentation avoids confusion with earlier versions.

Within the STYLAGE® range, XL carries the highest HA concentration (26mg/g) and is indicated when STYLAGE® L (24mg/g) or M (20mg/g) cannot achieve the required degree of structural correction. STYLAGE® L and M remain appropriate for moderate volume loss and deep wrinkle correction; S and SPECIAL LIPS serve superficial lines and lip precision, respectively.

Practitioners evaluating whether STYLAGE® is a good filler will find that the range is CE-marked, manufactured in France to pharmaceutical-grade standards, and built on IPN-Like Technology™ whose cohesive properties are supported in aesthetic medicine literature. The BI-FLEX® syringe further supports precise, controlled delivery at the deep-plane depths XL-grade work demands.

Indications & Clinical Use of STYLAGE® XL BI-FLEX® with Lidocaine Injection

This STYLAGE® dermal filler is indicated for severe volume loss and deep structural facial contouring in aesthetic medicine practice. Primary treatment areas include the cheeks, temples, midface, and jawline at the supraperiosteal or deep subcutaneous plane. Applications include cheekbone enhancement, chin projection, jawline definition, and the deep correction layer for nasolabial folds and marionette lines with a significant volume component.

STYLAGE® XL BI-FLEX® with Lidocaine injection is indicated when lighter STYLAGE® formulations cannot deliver the required volume or structural outcome. Patient selection should account for the degree of volume loss, the condition of the patient’s skin, and individual skin type.

This product is for licensed aesthetic medicine professionals with competence in deep-plane injections. Practitioners must follow aseptic technique, screen for contraindications including hypersensitivity to HA or amide-type anesthetics, and avoid intravascular injection.

Administration, Side Effects & Safety

STYLAGE® XL BI-FLEX® with Lidocaine is administered into the supraperiosteal or deep subcutaneous plane using the included needle configuration. The 23G 1¼” needles are suited to deep bolus placement, while the 27G ½” needles support more controlled subcutaneous delivery; needle selection should reflect technique and target depth. Co-formulated lidocaine provides anesthesia at the injection site; supplemental block anesthesia remains available at the practitioner’s discretion for extended sessions.

Post-treatment, patients should avoid sun exposure until redness and swelling resolve. Patients should also avoid strenuous physical activity, alcohol, and facial heat treatments in the immediate post-treatment period.

Common Adverse Events

• Redness
• Swelling
• Tenderness

These are transient and typically resolve within a few days. Bruising at the injection site may also occur. Deep-plane swelling can be more pronounced and longer-lasting than that seen with superficial fillers, and patients should be counseled accordingly.

Serious Adverse Events (Rare)

Rare but serious events include vascular occlusion, skin necrosis, and visual disturbance, which require prompt management. Practitioners should screen for hypersensitivity to HA or amide-type anesthetics before treatment.

Legal & Regulatory Status

STYLAGE® XL BI-FLEX® with Lidocaine is CE-marked and manufactured in France by Laboratories VIVACY for professional aesthetic use in the EU. As of 2026, it is not approved by the US FDA. Practitioners who plan to buy STYLAGE® XL BI-FLEX® wholesale and are seeking options in non-EU markets must first confirm the applicable regulatory status. Use is restricted to licensed medical professionals and registered aesthetic clinics.

Practitioners wishing to buy STYLAGE® or buy dermal fillers through an authorized channel should confirm product authenticity and documentation with their chosen distributor. For sourcing guidance, contact Medica Depot’s support representatives.

Citations

1. Pierre S, Liew S, Bernardin A. Basics of dermal filler rheology. Dermatol Surg. 2015;41(suppl 1):S120-S126. doi: 10.1097/dss.0000000000000334
2. Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009;35(suppl 1):302-312. doi: 10.1111/j.1524-4725.2008.01046.x
3. Beleznay K, Carruthers JDA, Humphrey S, Jones D. Avoiding and treating blindness from fillers. Dermatol Surg. 2015;41(10):1097-1117. doi: 10.1097/dss.0000000000000486

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.